<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00599287</url>
  </required_header>
  <id_info>
    <org_study_id>ICHYPDEL/002</org_study_id>
    <secondary_id>METC-UMCU 07/236</secondary_id>
    <nct_id>NCT00599287</nct_id>
  </id_info>
  <brief_title>Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients</brief_title>
  <official_title>Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients: a Randomized, Mono-blind Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot-trial is the feasibility of a large randomized, placebo controlled,
      doubleblind clinical trial to investigate the use of methylphenidate, rivastigmine or
      haloperidol in hypoactive ICU-delirium. In addition we will compare duration of delirium,
      severity of delirium, length of ICU/hospital stay and side effects between the different
      interventions.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inclusion rate too low due to a lack of eligible patients and difficulties obtaining informed
    consent.
  </why_stopped>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>duration of delirium</measure>
    <time_frame>Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of ICU-stay</measure>
    <time_frame>days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of in hospital stay</measure>
    <time_frame>days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delirium severity</measure>
    <time_frame>duration of delirium</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of side effects</measure>
    <time_frame>duration of intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylphenidate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivastigmine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Haloperidol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>Haloperidol 2,5 mg. 2 dd 1, oral. (if patient is 69 years or younger) Haloperidol 1 mg. 2 dd 1, oral (if patient is 70 years or older)</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Haldol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>Methylphenidate 5 mg. 2 dd 1, oral, increased every day with 10 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 30 mg./day</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Ritalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine</intervention_name>
    <description>Rivastigmine 1,5 mg. 2 dd 1, oral, increased every third day with 3 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 12 mg./day</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Exelon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 18 years

          -  Diagnosed as hypoactive delirium

          -  Informed consent given

        Exclusion Criteria:

          -  Pregnancy

          -  Epilepsy

          -  M. Parkinson

          -  Lewy-body dementia

          -  Prolonged QT-time

          -  Known allergy to the medicinals used

          -  Renal replacement therapy

          -  Hepatic encephalopathy

          -  Hyperthyroid

          -  Glaucoma

          -  Previous suicide attempts

          -  Syndrome of Gilles de la Tourette

          -  Patients which cannot receive the medication oral or through a nasogastric tube
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jozef Kesecioglu, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2008</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <name_title>prof. dr. J. Kesecioglu</name_title>
    <organization>University Medical Center Utrecht</organization>
  </responsible_party>
  <keyword>ICU delirium</keyword>
  <keyword>Hypoactive delirium</keyword>
  <keyword>Haloperidol</keyword>
  <keyword>Methylphenidate</keyword>
  <keyword>Rivastigmine</keyword>
  <keyword>Hypoactive ICU delirium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Hypokinesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Rivastigmine</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

